Medicinal Research Reviews

Article	Citations
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications	222
The role of hypoxia‐inducible factor 1 in tumor immune evasion	154
Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress‐ and aging‐related diseases	146
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)	143
Molecular targeting therapies for neuroblastoma: Progress and challenges	138
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?	133
Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention	129
Understanding the tumor microenvironment for effective immunotherapy	121
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions	110
Biologically active isoquinoline alkaloids covering 2014–2018	103
Mechanisms of melanocyte death in vitiligo	102
Small molecules regulating reactive oxygen species homeostasis for cancer therapy	102
A review in radiomics: Making personalized medicine a reality via routine imaging	97
Tripterygium wilfordii: An inspiring resource for rheumatoid arthritis treatment	96
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology	79
Therapeutic potential of phenylethanoid glycosides: A systematic review	78
Flavonoids as antiobesity agents: A review	78
Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship	78
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections	74
Phytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)	73
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases	71
Emerging roles of SIRT6 in human diseases and its modulators	70
Emerging carrier‐free nanosystems based on molecular self‐assembly of pure drugs for cancer therapy	68
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design	68
Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation	66

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases	66
Autophagy and cardiac diseases: Therapeutic potential of natural products	65
Emerging use of senolytics and senomorphics against aging and chronic diseases	65
Bioactive polymeric scaffolds for osteogenic repair and bone regenerative medicine	62
COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays	61
Skp2 in the ubiquitin‐proteasome system: A comprehensive review	61
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy	59
Direct targeting of β‐catenin in the Wnt signaling pathway: Current progress and perspectives	57
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing	57
Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy	54
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review	54
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications	51
Development of anti‐influenza agents from natural products	49
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases	46
Biologically active indolizidine alkaloids	46
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential	45
Strategies for designing proteolysis targeting chimaeras (PROTACs)	45
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism	45
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases	44
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition	43
Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol	40
Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease	39
Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles	39
Cistanches Herba, from an endangered species to a big brand of Chinese medicine	38
Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment	38
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities	38
A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation	37
Targeting telomerase for its advent in cancer therapeutics	37
Recent progress and new perspectives for diterpenoid biosynthesis in medicinal plants	37
Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence	37
Cardiac efficacy and toxicity of aconitine: A new frontier for the ancient poison	37
Extracellular vesicles: Emerging frontiers in wound healing	37
Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics	36
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use	36
The Yin and Yang of traditional Chinese and Western medicine	35
Pattern recognition receptor‐mediated inflammation in diabetic vascular complications	35
Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery	34
New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others	34
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets	34
Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease	34
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy	33
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer	33
The role of carbon monoxide, heme oxygenase 1, and the Nrf2 transcription factor in the modulation of chronic pain and their interactions with opioids and cannabinoids	32
Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update	32
Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds	32
The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies	32
Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness	31
Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach	31
Drug design targeting active posttranslational modification protein isoforms	31
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era	31

Pipeline of anti‐Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities	30
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective	30
Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer	30
Salinomycin as a potent anticancer stem cell agent: State of the art and future directions	29
Recent advances with 5‐HT3 modulators for neuropsychiatric and gastrointestinal disorders	28
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications	28
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives	27
An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface	27
Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin	27
Adipose‐derived stromal cells for nonhealing wounds: Emerging opportunities and challenges	26
Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics	26
The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome	26
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments	26
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response	26
The role of FOXOs and autophagy in cancer and metastasis—Implications in therapeutic development	25
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets	25
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy	24
Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors	24
Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease	23
Low‐molecular mimetics of nerve growth factor and brain‐derived neurotrophic factor: Design and pharmacological properties	23
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma	23
Inflammatory bowel disease biomarkers	23
Heat shock protein 60 and cardiovascular diseases: An intricate love‐hate story	23
A potential therapeutic strategy for prostatic disease by targeting the oral microbiome	22
Recent advances in natural anti‐HIV triterpenoids and analogs	22
Lipidomic landscape in cancer: Actionable insights for membrane‐based therapy and diagnoses	22
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors	22
Purine and pyrimidine transporters of pathogenic protozoa – conduits for therapeutic agents	22
Microglia‐derived galectin‐3 in neuroinflammation; a bittersweet ligand?	22
Recent pharmacological advances in the repurposing of artemisinin drugs	22
Combining stem cells in myocardial infarction: The road to superior repair?	22
(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy	22
Progress and perspective on hydrogen sulfide donors and their biomedical applications	21
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline	21
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges	21
Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies	21
Artemisinin‐derived dimers from a chemical perspective	21
The role of Wnt signaling in skin fibrosis	21
Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future	20
Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors	20
The antigen‐binding moiety in the driver's seat of CARs	20
The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases	20
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective	20
Epigenetic modifications in pancreas development, diabetes, and therapeutics	19
Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment	19
Therapeutic targets and potential agents for the treatment of COVID‐19	19
Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment	18
Targeted nanomedicines for the treatment of bone disease and regeneration	17
Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling	17
The lymphatic vasculature: An active and dynamic player in cancer progression	17
Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics	17
Incomplete autophagy: Trouble is a friend	17
ER stress and inflammation crosstalk in obesity	16
Emerging insights on the role of V‐ATPase in human diseases: Therapeutic challenges and opportunities	16
Applications of medicinal chemistry for drug discovery against Acanthamoeba infections	16
QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents	16
Revisiting prostate cancer metabolism: From metabolites to disease and therapy	16
Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery	16
Propolis: A useful agent on psychiatric and neurological disorders? A focus on CAPE and pinocembrin components	16
Ribosome‐targeting antibacterial agents: Advances, challenges, and opportunities	16
Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate?	15
Repurposing drugs to fight aging: The difficult path from bench to bedside	15
Recent progresses and remaining challenges for the detection of Zika virus	15
Liquid biopsy technologies for hematological diseases	15
1,3‐Diazepine: A privileged scaffold in medicinal chemistry	15
How selective are clinical CDK4/6 inhibitors?	14
Application or function of citric acid in drug delivery platforms	14
Mesenchymal stromal cell therapy for pancreatitis: Progress and challenges	14
The newly discovered role of endocytosis in artemisinin resistance	14
Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery	14
Therapeutic antisense oligonucleotides for movement disorders	14
Mitochondrial quality control proteases and their modulation for cancer therapy	14
MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies	13
Recent advances in the design of choline kinase α inhibitors and the molecular basis of their inhibition	13
Mechanism of activation and the rewired network: New drug design concepts	13
Targeting hepatocyte growth factor/c‐mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies	13
In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches	13
Natural products as Zika antivirals	13
Recent advances in proteome‐wide label‐free target deconvolution for bioactive small molecules	12
Peroral targeting of drug micro or nanocarriers to sites beyond the gastrointestinal tract	12

Recent developments in targeting genes and pathways by RNAi‐based approaches in colorectal cancer	12
Recent developments in controlling sternal wound infection after cardiac surgery and measures to enhance sternal healing	12
Nanotechnology‐based electrochemical biosensors for monitoring breast cancer biomarkers	11
Toward the next generation of vascularized human neural organoids	11
Recent progress in the imaging of c‐Met aberrant cancers with positron emission tomography	11
Small‐molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria‐related diseases	11
Advances in ameliorating inflammatory diseases and cancers by andrographolide: Pharmacokinetics, pharmacodynamics, and perspective	11
Small molecules as modulators of regulated cell death against ischemia/reperfusion injury	11
Cell transplantation and secretome based approaches in spinal cord injury regenerative medicine	10
β3‐Adrenoceptor, a novel player in the round‐trip from neonatal diseases to cancer: Suggestive clues from embryo	10
The adenosinergic pathway in mesenchymal stem cell fate and functions	10
Is viral E6 oncoprotein a viable target? A critical analysis in the context of cervical cancer	10
Natural products as geroprotectors: An autophagy perspective	9
Modern approaches in gene therapy of motor neuron diseases	9
The biology and inhibition of glucose‐regulated protein 94/gp96	9
Cardiovascular therapeutics: A new potential for anxiety treatment?	9
Recent progress and structural analyses of domain‐selective BET inhibitors	9
Epigenetic modification in alcohol‐related liver diseases	9
Purinergic receptors modulators: An emerging pharmacological tool for disease management	9
Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG‐I‐like receptors	8
Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis	8
Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi‐active components combination	8
Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders	8
Bacterial proton motive force as an unprecedented target to control antimicrobial resistance	8
New drug approvals for 2022: Synthesis and clinical applications	8
Neurodegenerative disorders—Searching for targets and new ways of diseases treatment	8
Genetically modified cancer vaccines: Current status and future prospects	8
Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases	7
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development	7
An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indications	7
The regulatory factors and pathological roles of autophagy‐related protein 4 in diverse diseases: Recent research advances	7
Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease	7
Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics	7
Pharmacotranscriptomics of peptide drugs with neuroprotective properties	7
Connecting the dots: Targeting the microbiome in drug toxicity	7